Centre of Evidence Based Dermatology

The Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS)

 THESEUSteam
The THESEUS team includes people with hidradenitis suppurativa, dermatologists, GPs, surgeons and research experts.
 


Hidradenitis suppurativa is a long term, painful skin condition that affects approximately 1% of adults. It involves boils in areas such as the armpits and groins. The THESEUS study has been developed to inform the design of future hidradenitis suppurativa trials and will help us to understand how hidradenitis suppurativa treatments are currently used. The study has been developed with the support of the UK Dermatology Clinical Trials Network 

Cardiff-University-logo-for-website THESEUS is a collaborative study being led by the Centre for Trials Research at Cardiff University.

Contact the trial team
 
Interested in taking part? More details on what the study involves, who can take part and where the study is recruiting are listed in the following sections.
 

Key information

What does THESEUS involve?

THESEUS is investigating five treatments: two medicines (doxycycline, clindamycin & rifampicin), two types of surgery (deroofing and excision), and laser treatment.  Further details about what each of these treatment choices entails can be found in the treatment decision grid.

The choice of treatment will be decided by the participant and their doctor, and will depend upon what treatment is available locally and severity of disease.

For full details of what's involved in taking part in this study, please see the patient information leaflet.

 
Who can take part in the study?

You may be eligible to take part in the THESEUS study if you:

  • Are 18 years of age or older
  • Have a diagnosis of active hidradenitis suppurativa which is not controlled by your current treatment.

You would not be eligible to take part if you are pregnant or breast feeding.

 
Who do I contact about participating in the study?

The table below details the hospital sites involved in the THESEUS study. If you are close to one of these hospitals and are interested in taking part in the study, please get in touch using the email or telephone contact information below.

 Site Contact name and email Telephone
 Barnsley  Nicola Lancaster; Susan Hope  01226 435084
 Broomfield Hospital  Natalie Fox; Karen Cranmer  01245 515127
 Cardiff  Delyth Braim; Beverley Gambles  02929742298
 Forth Valley  Fiona Collier   01786434096 
 Guys and St Thomas  Tendai Kadiyirire  02071887188 ext 86353
 Newcastle  Newcastle dermatology research team  0191 2823568
 Oxford  Melanie Westmoreland  01865 228252
 Salisbury  Sarah Diment; Vicky King; Helen Pidgeon  01722 336262 ext 4459
 Stoke Mandeville   Judith AbramsIona Burn  01296 315832

 
Clinic visits will be arranged to fit with normal clinic appointments. Please note that we are not able to reimburse travel costs. 

 
Who is funding the study?
The research is being funded by the UK Government, through the National Institute of Health Research Health Technology Assessment (NIHR HTA) programme.
 

 

Publications

Population-based Clinical Practice Research Datalink studyusing algorithm modelling to identify the true burden of hidradenitis suppurativa
J.R. Ingram et al. British Journal of Dermatology (2018) 

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
L. Thorlacius and J.R. Ingram et al. British Journal of Dermatology (2018) 

Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
J.R. Ingram et al. British Journal of Dermatology  (2016) 

The Hidradenitis Suppurativa Priority Setting Partnership
J.R. Ingram et al. British Journal of Dermatology (2014)  


This study is funded by the National Institute for Health Research (NIHR) [Health Technology Assessment Programme (HTA Project: 17/98/01)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Centre of Evidence Based Dermatology

The University of Nottingham
Applied Health Research Building
University Park, Nottingham
NG7 2RD


telephone: +44 (0) 115 84 68631
email: cebd@nottingham.ac.uk